Gene S | List of Frontiers open access articles

Original Research

Published on 20 Feb 2024

Effect of miR-17 on Polygonum Cillinerve polysaccharide against transmissible gastroenteritis virus

in Veterinary Infectious Diseases

Xueqin Duan
Mengxin Xu
Yunying Wang
Nishang Liu
Xingchen Wang
Yingqiu Liu
Weimin Zhang
Wuren Ma
Lin Ma
Yunpeng Fan

Frontiers in Veterinary Science

doi 10.3389/fvets.2024.1360102

2,478 views
1 citation

Original Research

Published on 12 Dec 2019

Selective Engagement of FcγRIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection

in Vaccines and Molecular Therapeutics

Dorien De Vlieger
Katja Hoffmann
Inge Van Molle
Wim Nerinckx
Lien Van Hoecke
Marlies Ballegeer
Sarah Creytens
Han Remaut
Hartmut Hengel
Bert Schepens

Frontiers in Immunology

doi 10.3389/fimmu.2019.02920

8,218 views
22 citations

Original Research

Published on 04 Aug 2023

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia

in Vaccines and Molecular Therapeutics

Lauren A. Chang
Angela Choi
Raveen Rathnasinghe
Prajakta Warang
Moataz Noureddine
Sonia Jangra
Yong Chen
Bruno G. De Geest
Michael Schotsaert

Frontiers in Immunology

doi 10.3389/fimmu.2023.1217181

6,607 views
22 citations

Original Research

Published on 15 Jun 2022

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern

in Vaccines and Molecular Therapeutics

Mandy Schwarze
Andor Krizsan
Alexandra Brakel
Fabian Pohl
Daniela Volke
Ralf Hoffmann

Frontiers in Immunology

doi 10.3389/fimmu.2022.915034

4,405 views
11 citations

Mini Review

Published on 10 Jan 2020

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

in Vaccines and Molecular Therapeutics

Nimitha R. Mathew
Davide Angeletti

Frontiers in Immunology

doi 10.3389/fimmu.2019.02997

20,608 views
24 citations

Original Research

Published on 29 Jul 2021

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity

in Vaccines and Molecular Therapeutics

Antonella Scaglione
Silvana Opp
Alicia Hurtado
Ziyan Lin
Christine Pampeno
Maria G. Noval
Sara A. Thannickal
Kenneth A. Stapleford
Daniel Meruelo

Frontiers in Immunology

doi 10.3389/fimmu.2021.719077

7,073 views
18 citations

Perspective

Published on 19 Jan 2022

Enhanced Immune Responses by Virus-Mimetic Polymeric Nanostructures Against Infectious Diseases

in Vaccines and Molecular Therapeutics

Xinpei Li
Shengqiu Liu
Panchao Yin
Kun Chen

Frontiers in Immunology

doi 10.3389/fimmu.2021.804416

4,110 views
5 citations

Perspective

Published on 11 Jun 2021

Targeting Future Pandemics, a Case for De Novo Purine Synthesis and Basic Research

in Vaccines and Molecular Therapeutics

Randall C. Mazzarino

Frontiers in Immunology

doi 10.3389/fimmu.2021.694300

4,885 views
7 citations

Original Research

Published on 22 Mar 2021

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

in Vaccines and Molecular Therapeutics

Xiaojian Han
Yingming Wang
Shenglong Li
Chao Hu
Tingting Li
Chenjian Gu
Kai Wang
Meiying Shen
Jianwei Wang
Jie Hu

Frontiers in Immunology

doi 10.3389/fimmu.2021.653189

10,463 views
31 citations

Original Research

Published on 13 Nov 2020

Safety, Immunogenicity, and Effectiveness of Defective Viral Particles Arising in Mast Cells Against Influenza in Mice

in Vaccines and Molecular Therapeutics

Caiyun Huo
Jijing Tian
Jinlong Cheng
Jin Xiao
Mingyong Chen
Shumei Zou
Haiyan Tian
Ming Wang
Huiling Sun
Yanxin Hu

Frontiers in Immunology

doi 10.3389/fimmu.2020.585254

3,505 views
9 citations

Original Research

Published on 14 Jul 2021

Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections

in Vaccines and Molecular Therapeutics

Ting-Hsuan Chen
Ya-Lin Yang
Jia-Tsrong Jan
Chung-Chu Chen
Suh-Chin Wu

Frontiers in Immunology

doi 10.3389/fimmu.2021.692700

6,132 views
12 citations

Original Research

Published on 04 May 2022

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity

in Vaccines and Molecular Therapeutics

Kalyan Pande
Scott A. Hollingsworth
Miranda Sam
Qinshan Gao
Sujata Singh
Anasuya Saha
Karin Vroom
Xiaohong Shirley Ma
Tres Brazell
Dan Gorman

Frontiers in Immunology

doi 10.3389/fimmu.2022.864775

5,391 views
4 citations

Original Research

Published on 18 Nov 2021

Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats

in Vaccines and Molecular Therapeutics

Johnstone Tcheou
Ariel Raskin
Gagandeep Singh
Hisaaki Kawabata
Dominika Bielak
Weina Sun
Irene González-Domínguez
D Noah Sather
Adolfo García-Sastre
Peter Palese

Frontiers in Immunology

doi 10.3389/fimmu.2021.791764

9,453 views
29 citations

Original Research

Published on 12 Jan 2022

DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model

in Vaccines and Molecular Therapeutics

Levi A. Tamming
Diana Duque
Anh Tran
Wanyue Zhang
Annabelle Pfeifle
Emmanuel Laryea
Jianguo Wu
Sathya N. Thulasi Raman
Caroline Gravel
Marsha S. Russell

Frontiers in Immunology

doi 10.3389/fimmu.2021.785349

9,110 views
20 citations

Original Research

Published on 09 Dec 2021

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

in Vaccines and Molecular Therapeutics

Maristella Pitzalis
Maria Laura Idda
Valeria Lodde
Annalisa Loizedda
Monia Lobina
Magdalena Zoledziewska
Francesca Virdis
Giuseppe Delogu
Federica Pirinu
Maria Giuseppina Marini

Frontiers in Immunology

doi 10.3389/fimmu.2021.781843

7,224 views
53 citations

Original Research

Published on 26 Aug 2021

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals

in Vaccines and Molecular Therapeutics

Yosuke Hirotsu
Kenji Amemiya
Hiroki Sugiura
Miyuki Shinohara
Mika Takatori
Hitoshi Mochizuki
Masao Omata

Frontiers in Immunology

doi 10.3389/fimmu.2021.722766

7,816 views
21 citations

Articles

Effect of miR-17 on Polygonum Cillinerve polysaccharide against transmissible gastroenteritis virus

Selective Engagement of FcγRIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity

Enhanced Immune Responses by Virus-Mimetic Polymeric Nanostructures Against Infectious Diseases

Targeting Future Pandemics, a Case for De Novo Purine Synthesis and Basic Research

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

Safety, Immunogenicity, and Effectiveness of Defective Viral Particles Arising in Mast Cells Against Influenza in Mice

Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity

Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats

DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals